Length of Initial Prescription at Hospital Discharge and Long-Term Medication Adherence for Elderly, Post-Myocardial Infarction Patients: Protocol for an Interrupted Time Series Study

J D Schwalm, Noah M Ivers, Zachary Bouck, Monica Taljaard, Madhu K Natarajan, Lisa Dolovich, Kednapa Thavorn, Tara McCready, Erin O'Brien, Jeremy M Grimshaw, J D Schwalm, Noah M Ivers, Zachary Bouck, Monica Taljaard, Madhu K Natarajan, Lisa Dolovich, Kednapa Thavorn, Tara McCready, Erin O'Brien, Jeremy M Grimshaw

Abstract

Background: Based on high-quality evidence, guidelines recommend the long-term use of secondary prevention medications post-myocardial infarction (MI) to avoid recurrent cardiovascular events and death. Unfortunately, discontinuation of recommended medications post-MI is common. Observational evidence suggests that prescriptions covering a longer duration at discharge from hospital are associated with greater long-term medication adherence. The following is a proposal for the first interventional study to evaluate the impact of longer prescription duration at discharge post-MI on long-term medication adherence.

Objective: The overarching goal of this study is to reduce morbidity and mortality among post-MI patients through improved long-term cardiac medication adherence. The specific objectives include the following. First, we will assess whether long-term cardiac medication adherence improves among elderly, post-MI patients following the implementation of (1) standardized discharge prescription forms with 90-day prescriptions and 3 repeats for recommended cardiac medication classes, in combination with education and (2) education alone compared to (3) usual care. Second, we will assess the cost implications of prolonged initial discharge prescriptions compared with usual care. Third, we will compare clinical outcomes between longer (>60 days) versus shorter prescription durations. Fourth, we will collect baseline information to inform a multicenter interventional study.

Methods: We will conduct a quasiexperimental, interrupted time series design to evaluate the impact of a multifaceted intervention to implement longer duration prescriptions versus usual care on long-term cardiac medication adherence among post-MI patients. Intervention groups and their corresponding settings include: (1) intervention group 1: 1 cardiac center and 1 noncardiac hospital allocated to receive standardized discharge prescription forms supporting the dispensation of 90 days' worth of cardiac medications with 3 repeats, coupled with education; (2) intervention group 2: 4 sites (including 1 cardiac center) allocated to receive education only; and (3) control group: all remaining hospitals within the province that did not receive an intervention (ie, usual care). Administrative databases will be used to measure all outcomes. Adherence to 4 classes of cardiac medications - statins, beta blockers, angiotensin system inhibitors, and secondary antiplatelets (ie, prasugrel, clopidogrel, or ticagrelor) - will be assessed.

Results: Enrollment began in September 2017, and results are expected to be analyzed in late 2020.

Conclusions: The results have the potential to redefine best practices regarding discharge prescribing policies for patients post-MI. A policy of standardized maximum-duration prescriptions at the time of discharge post-MI is a simple intervention that has the potential to significantly improve long-term medication adherence, thus decreasing cardiac morbidity and mortality. If effective, this low-cost intervention to implement longer duration prescriptions post-MI could be easily scaled.

Trial registration: ClinicalTrials.gov NCT03257579; https://ichgcp.net/clinical-trials-registry/NCT03257579.

International registered report identifier (irrid): DERR1-10.2196/18981.

Keywords: adherence; cardiology; discharge; elderly; heart; intervention; medication; policy change; post-myocardial infarction; prescription; prevention; secondary prevention; standardized discharge prescription form.

Conflict of interest statement

Conflicts of Interest: None declared.

©J D Schwalm, Noah M Ivers, Zachary Bouck, Monica Taljaard, Madhu K Natarajan, Lisa Dolovich, Kednapa Thavorn, Tara McCready, Erin O'Brien, Jeremy M Grimshaw. Originally published in JMIR Research Protocols (http://www.researchprotocols.org), 04.11.2020.

Figures

Figure 1
Figure 1
Persistence with secondary prevention medications after angiography. ACE: angiotensin-converting enzyme.
Figure 2
Figure 2
Intervention and control groups in the Myocardial Infarction Prescription Adherence Duration (MIPAD) study.
Figure 3
Figure 3
Example discharge prescription from Hamilton Health Sciences with intervention revisions circled.
Figure 4
Figure 4
Flow of participants into the study during the pre-intervention period (preliminary data used for power calculation). Notes: Patient age determined at procedure date – 120 days. CAD: coronary artery disease; CCN-CR: Cardiac Care Network – Cardiac Registry; CIHI-DAD: Canadian Institute for Health Information - discharge abstract database; MI: myocardial infarction; RPDB: registered persons database.

References

    1. Smith SC Jr, Benjamin EJ, Bonow RO, Braun LT, Creager MA, Franklin BA, Gibbons RJ, Grundy SM, Hiratzka LF, Jones DW, Lloyd-Jones DM, Minissian M, Mosca L, Peterson ED, Sacco RL, Spertus J, Stein JH, Taubert KA. AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update. Circulation. 2011 Nov 29;124(22):2458–2473. doi: 10.1161/CIR.0b013e318235eb4d. doi: 10.1161/CIR.0b013e318235eb4d.
    1. Antman EM, Hand M, Armstrong PW, Bates ER, Green LA, Halasyamani LK, Hochman JS, Krumholz HM, Lamas GA, Mullany CJ, Pearle DL, Sloan MA, Smith SC, 2004 Writing Committee Members. Anbe DT, Kushner FG, Ornato JP, Jacobs AK, Adams CD, Anderson JL, Buller CE, Creager MA, Ettinger SM, Halperin JL, Hunt SA, Lytle BW, Nishimura R, Page RL, Riegel B, Tarkington LG, Yancy CW. 2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: developed in collaboration With the Canadian Cardiovascular Society endorsed by the American Academy of Family Physicians: 2007 Writing Group to Review New Evidence and Update the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction, Writing on Behalf of the 2004 Writing Committee. Circulation. 2008 Jan 15;117(2):296–329. doi: 10.1161/CIRCULATIONAHA.107.188209.
    1. Fitchett DH, Theroux P, Brophy JM, Cantor WJ, Cox JL, Gupta M, Kertland H, Mehta SR, Welsh RC, Goodman SG. Assessment and management of acute coronary syndromes (ACS): a Canadian perspective on current guideline-recommended treatment--part 2: ST-segment elevation ACS. Can J Cardiol. 2011;27 Suppl A:S387–401. doi: 10.1016/j.cjca.2011.08.110.
    1. Ivers NM, Schwalm JD, Jackevicius CA, Guo H, Tu JV, Natarajan M. Length of initial prescription at hospital discharge and long-term medication adherence for elderly patients with coronary artery disease: a population-level study. Can J Cardiol. 2013 Nov;29(11):1408–14. doi: 10.1016/j.cjca.2013.04.009.
    1. Tu JV, Donovan LR, Lee DS, Wang JT, Austin PC, Alter DA, Ko DT. Effectiveness of public report cards for improving the quality of cardiac care: the EFFECT study: a randomized trial. JAMA. 2009 Dec 02;302(21):2330–7. doi: 10.1001/jama.2009.1731.
    1. Ahmad M, Schwalm JD, Velianou JL, Natarajan MK. Impact of routine in-hospital assessment of low-density lipoprotein levels and standardized orders on statin therapy in patients undergoing percutaneous coronary interventions. J Invasive Cardiol. 2005 Oct;17(10):518–20.
    1. Newby LK, LaPointe NM, Chen AY, Kramer JM, Hammill BG, DeLong ER, Muhlbaier LH, Califf RM. Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease. Circulation. 2006 Jan 17;113(2):203–12. doi: 10.1161/CIRCULATIONAHA.105.505636.
    1. Hudson M, Richard H, Pilote L. Parabolas of medication use and discontinuation after myocardial infarction--are we closing the treatment gap? Pharmacoepidemiol Drug Saf. 2007 Jul;16(7):773–85. doi: 10.1002/pds.1414.
    1. Shah ND, Dunlay SM, Ting HH, Montori VM, Thomas RJ, Wagie AE, Roger VL. Long-term medication adherence after myocardial infarction: experience of a community. Am J Med. 2009 Oct;122(10):961.e7–13. doi: 10.1016/j.amjmed.2008.12.021.
    1. Rasmussen JN, Chong A, Alter DA. Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. JAMA. 2007 Jan 10;297(2):177–86. doi: 10.1001/jama.297.2.177.
    1. Ho PM, Magid DJ, Shetterly SM, Olson KL, Maddox TM, Peterson PN, Masoudi FA, Rumsfeld JS. Medication nonadherence is associated with a broad range of adverse outcomes in patients with coronary artery disease. Am Heart J. 2008 Apr;155(4):772–9. doi: 10.1016/j.ahj.2007.12.011.
    1. Ho PM, Bryson CL, Rumsfeld JS. Medication adherence: its importance in cardiovascular outcomes. Circulation. 2009 Jun 16;119(23):3028–35. doi: 10.1161/CIRCULATIONAHA.108.768986.
    1. Spertus JA, Kettelkamp R, Vance C, Decker C, Jones PG, Rumsfeld JS, Messenger JC, Khanal S, Peterson ED, Bach RG, Krumholz HM, Cohen DJ. Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry. Circulation. 2006 Jun 20;113(24):2803–9. doi: 10.1161/CIRCULATIONAHA.106.618066.
    1. Hope CJ, Wu J, Tu W, Young J, Murray MD. Association of medication adherence, knowledge, and skills with emergency department visits by adults 50 years or older with congestive heart failure. Am J Health Syst Pharm. 2004 Oct 01;61(19):2043–9. doi: 10.1093/ajhp/61.19.2043.
    1. Batal HA, Krantz MJ, Dale RA, Mehler PS, Steiner JF. Impact of prescription size on statin adherence and cholesterol levels. BMC Health Serv Res. 2007 Oct 25;7:175. doi: 10.1186/1472-6963-7-175.
    1. Steiner JF, Robbins LJ, Roth SC, Hammond WS. The effect of prescription size on acquisition of maintenance medications. J Gen Intern Med. 1993 Jun;8(6):306–310. doi: 10.1007/bf02600143.
    1. De Geest S, Sabaté E. Adherence to Long-Term Therapies: Evidence for Action. European Journal of Cardiovascular Nursing. 2016 Jun 22;2(4):323–323. doi: 10.1016/s1474-5151(03)00091-4.
    1. Presseau J, Schwalm JD, Grimshaw JM, Witteman HO, Natarajan MK, Linklater S, Sullivan K, Ivers NM. Identifying determinants of medication adherence following myocardial infarction using the Theoretical Domains Framework and the Health Action Process Approach. Psychol Health. 2017 Oct;32(10):1176–1194. doi: 10.1080/08870446.2016.1260724.
    1. Lau E, Papaioannou A, Dolovich L, Adachi J, Sawka AM, Burns S, Nair K, Pathak A. Patients' adherence to osteoporosis therapy: exploring the perceptions of postmenopausal women. Can Fam Physician. 2008 Mar;54(3):394–402.
    1. Dolovich L, Nair K, Sellors C, Lohfeld L, Lee A, Levine M. Do patients' expectations influence their use of medications? Qualitative study. Can Fam Physician. 2008 Mar;54(3):384–93.
    1. Schwalm JD, Ivers NM, Natarajan MK, Taljaard M, Rao-Melacini P, Witteman HO, Zwarenstein M, Grimshaw JM. Cluster randomized controlled trial of Delayed Educational Reminders for Long-term Medication Adherence in ST-Elevation Myocardial Infarction (DERLA-STEMI) Am Heart J. 2015 Nov;170(5):903–13. doi: 10.1016/j.ahj.2015.08.014.
    1. Mueller SK, Sponsler KC, Kripalani S, Schnipper JL. Hospital-based medication reconciliation practices: a systematic review. Arch Intern Med. 2012 Jul 23;172(14):1057–69. doi: 10.1001/archinternmed.2012.2246.
    1. Shadish WR, Cook TD, Campbell DT. Experimental and quasi-experimental designs for generalized causal inference. Boston, MA: Houghton Mifflin; 2002. Quasi-experiments: interrupted time-series designs.
    1. Lopez Bernal J, Cummins S, Gasparrini A. The use of controls in interrupted time series studies of public health interventions. Int J Epidemiol. 2018 Dec 01;47(6):2082–2093. doi: 10.1093/ije/dyy135.
    1. Straus S, Tetroe J, Graham ID, editors. Knowledge translation in health care: moving from evidence to practice, 2nd edition. Chichester, West Sussex: Wiley BMJ/Books; 2013. Aug,
    1. Cardiac Care Network . CCN Registries: Data Entry Reference Manual and Data Standards. Ontario, Canada: Cardiac Care Network; 2017. Sep,
    1. Ivers NM, Schwalm JD, Witteman HO, Presseau J, Taljaard M, McCready T, Bosiak B, Cunningham J, Smarz S, Desveaux L, Tu JV, Atzema C, Oakes G, Isaranuwatchai W, Grace SL, Bhatia RS, Natarajan M, Grimshaw JM. Interventions Supporting Long-term Adherence aNd Decreasing cardiovascular events (ISLAND): Pragmatic randomized trial protocol. Am Heart J. 2017 Aug;190:64–75. doi: 10.1016/j.ahj.2017.05.007.
    1. Discharge abstract database metadata (DAD) Canadian Institute for Health Information (CIHI) 2020. [2019-11-01]. .
    1. Tran C, Wijeysundera HC, Qui F, Tu JV, Bhatia RS. Comparing the ambulatory care and outcomes for rural and urban patients with chronic ischemic heart disease: a population-based cohort study. Circ Cardiovasc Qual Outcomes. 2014 Nov;7(6):835–43. doi: 10.1161/CIRCOUTCOMES.114.001076.
    1. Nau DP. Proportion of days covered (PDC) as a preferred method of measuring medication adherence. 2012. [2020-10-08]. .
    1. Leslie RS. Using arrays to calculate medication utilization. SAS Global Forum 2007; April 16-19, 2007; Orlando, FL. 2007.
    1. Martin BC, Wiley-Exley EK, Richards S, Domino ME, Carey TS, Sleath BL. Contrasting measures of adherence with simple drug use, medication switching, and therapeutic duplication. Ann Pharmacother. 2009 Jan;43(1):36–44. doi: 10.1345/aph.1K671.
    1. Kozma CM, Dickson M, Phillips AL, Meletiche DM. Medication possession ratio: implications of using fixed and variable observation periods in assessing adherence with disease-modifying drugs in patients with multiple sclerosis. Patient Prefer Adherence. 2013;7:509–16. doi: 10.2147/PPA.S40736. doi: 10.2147/PPA.S40736.
    1. Rasmussen JN, Chong A, Alter DA. Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. JAMA. 2007 Jan 10;297(2):177–86. doi: 10.1001/jama.297.2.177.
    1. Wagner AK, Soumerai SB, Zhang F, Ross-Degnan D. Segmented regression analysis of interrupted time series studies in medication use research. J Clin Pharm Ther. 2002 Aug;27(4):299–309. doi: 10.1046/j.1365-2710.2002.00430.x.
    1. Taljaard M, McKenzie JE, Ramsay CR, Grimshaw JM. The use of segmented regression in analysing interrupted time series studies: an example in pre-hospital ambulance care. Implement Sci. 2014 Jun 19;9:77. doi: 10.1186/1748-5908-9-77.
    1. Zhang F, Wagner AK, Ross-Degnan D. Simulation-based power calculation for designing interrupted time series analyses of health policy interventions. J Clin Epidemiol. 2011 Nov;64(11):1252–61. doi: 10.1016/j.jclinepi.2011.02.007.
    1. Becerra V, Gracia A, Desai K, Abogunrin S, Brand S, Chapman R, García Alonso F, Fuster V, Sanz G. Cost-effectiveness and public health benefit of secondary cardiovascular disease prevention from improved adherence using a polypill in the UK. BMJ Open. 2015 May 09;5(5):e007111. doi: 10.1136/bmjopen-2014-007111.
    1. Working Group on the Summit on Combination Therapy for CVD. Yusuf S, Attaran A, Bosch J, Joseph P, Lonn E, McCready T, Mente A, Nieuwlaat R, Pais P, Rodgers A, Schwalm JD, Smith R, Teo K, Xavier D. Combination pharmacotherapy to prevent cardiovascular disease: present status and challenges. Eur Heart J. 2014 Feb;35(6):353–64. doi: 10.1093/eurheartj/eht407.
    1. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA, PLATO Investigators. Freij A, Thorsén Mona. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009 Sep 10;361(11):1045–57. doi: 10.1056/NEJMoa0904327.

Source: PubMed

3
구독하다